Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 16, 2021

Study Completion Date

March 4, 2021

Conditions
Clear Cell Metastatic Renal Cell Carcinoma
Interventions
RADIATION

Stereotactic radiotherapy

SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.

Trial Locations (12)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency, Vancouver

R3E 0V9

Manitoba CancerCare Institute, Winnipeg

B3H 2Y9

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4L6

London Health Sciences Centre, London

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

M4N 3M5

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H3G 1A4

McGill University Health Centre, Montreal

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER